Sanofi will exit cancer drug developer Impact Biomedicines in an acquistion by Celgene that consists of $1.1bn up front and potentially billions in milestone payments.
Pharmaceutical firm Celgene has agreed to acquire US-based cancer treatment developer Impact Biomedicines in a $1.1bn deal that will give an exit to fellow pharmaceutical company Sanofi.
Impact is developing therapies for complex cancers based on fedratinib, an oral small-molecule inhibitor of the JAK2 kinase enzyme, which will address bone marrow disorders polycythemia vera and myelofibrosis.
The acquisition deal involves Celgene paying $1.1bn up front, but up to $1.4bn more could come from milestones linked to approvals for myelofibrosis and…
